GlaxoSmithKline Plc (GSK)

40.82
0.39 0.95
NYSE : Health Technology
Prev Close 41.21
Open 40.94
Day Low/High 40.88 / 41.08
52 Wk Low/High 31.43 / 48.25
Volume 566.02K
Avg Volume 3.18M
Exchange NYSE
Shares Outstanding 2.51B
Market Cap 102.02B
EPS 2.40
P/E Ratio 23.70
Div & Yield 1.97 (4.86%)
9 Stocks for the Bank of England's Corporate-Bond Purchases

9 Stocks for the Bank of England's Corporate-Bond Purchases

Which stocks will be most favored by the corporate-bond purchases?

4 Stocks to Buy in This Vulnerable Market

4 Stocks to Buy in This Vulnerable Market

This market is like a leaky helium balloon; watch out for sudden downdrafts.

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

The drug maker continued to rally Monday.

GlaxoSmithKline Inks Medical 'Bioelectronics' Partnership With Alphabet

GlaxoSmithKline Inks Medical 'Bioelectronics' Partnership With Alphabet

The pharmaceutical giant is teaming up with Google's parent with as much as $715 million in joint investments.

Morning Movers: GSK, GOOGL, SCTY, TSLA

Morning Movers: GSK, GOOGL, SCTY, TSLA

GlaxoSmithKline and Google's parent Alphabet announced their joint plan to pioneer a new form of electronic medical treatment.

Grab a Bit of Britain With FTSE 100 ETF

Grab a Bit of Britain With FTSE 100 ETF

The U.K. isn't going anywhere Brexit vote notwithstanding, and here's a way to get on the most business-friendly state across the pond.

European Stocks: What's Your Pain Tolerance?

If you think the best thing to do post-Brexit is buy more, here are 4 to consider.

GlaxoSmithKline Has No Cure for Sideways Action

GlaxoSmithKline Has No Cure for Sideways Action

GSK has been largely stuck between $44 on the upside and $37 on the downside for the past 12 months.

Sizing Up Johnson & Johnson's Talcum Fallout

Sizing Up Johnson & Johnson's Talcum Fallout

The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.

Jim Cramer Likes Johnson & Johnson, Allergan in the Pharma Sector

Jim Cramer Likes Johnson & Johnson, Allergan in the Pharma Sector

Jim Cramer says it you are going to own a drug stock, invest in Allergan or Johnson & Johnson.

Jim Cramer Says This Will Be a Good Quarter for 3-M, Buy GE on a Dip

Jim Cramer Says This Will Be a Good Quarter for 3-M, Buy GE on a Dip

Jim Cramer says UnitedHealth's stock is going much higher, and it is a 'terrific' name to own.

Glaxo, IP and PetMed Poised to Go Higher

Glaxo, IP and PetMed Poised to Go Higher

Shares of GlaxoSmithKline are up a pleasant 5% in 2016 and it currently sports a healthy 6.5% dividend yield.

Tax Clampdown Prompts Pfizer to Scrap Allergan Purchase

CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

GlaxoSmithKline's Condition Isn't Improving

GlaxoSmithKline's Condition Isn't Improving

With the short-term trend neutral and the longer-term trend down be on guard for a break lower to around $35.

3 Pharma Stocks to Heal Your Portfolio

Dividend yield is the determining factor in this strategy.

Novice Trade: GlaxoSmithKline

Novice Trade: GlaxoSmithKline

Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.

Betting on Fallen Angels Could Be Heavenly

Betting on Fallen Angels Could Be Heavenly

If you have an appetite for risk, there are buying opportunities.

2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.

Midday Report: Disney Drops on ESPN Concerns; Stocks Fall

Midday Report: Disney Drops on ESPN Concerns; Stocks Fall

Stocks were sharply lower at midday in a volatile session to end the week.

3 'Wide Moat' Stocks That Could Float Your Boat

This trio enjoys competitive advantages that should serve investors well over the long haul.

Don't Short the Gap, Go Long (Plus: GSK, WHR, AA)

Don't Short the Gap, Go Long (Plus: GSK, WHR, AA)

Use $24 or $26 as a stop point. 

GlaxoSmithKline Sets Up for a Rally; Shares Could Rise 25%

GlaxoSmithKline Sets Up for a Rally; Shares Could Rise 25%

The stock has put in a tradable low that can support a respectable rally that could carry into early 2016.

What to Watch Wednesday: Walgreens Boots Alliance Takes the Spotlight

What to Watch Wednesday: Walgreens Boots Alliance Takes the Spotlight

For Wednesday October 28, TheStreet awaits quarterly results from Walgreens Boots Alliance (WBA), Mondelez (MDLZ), Fiat Chrysler (FCAU), Amgen (AMGN), PayPal (PYPL), Buffalo Wild Wings (BWLD) and more.

A Small Pharma Stock With Big Potential

A Small Pharma Stock With Big Potential

Pernix looks poised for a strong 2016.

Is the Worst Over for GlaxoSmithKline?

Is the Worst Over for GlaxoSmithKline?

The charts show that the stock is due for a rally.

Eli Lilly Shares Are Full of Life With 30% Upside

Eli Lilly Shares Are Full of Life With 30% Upside

Eli Lilly has bucked the downtrend in other pharma names, and its chart is pointed higher.

Don't Miss These 3 Biotech Stocks

Don't Miss These 3 Biotech Stocks

Investors have been distracted by the Fed, and that's a shame.

U.S. Stocks Open Higher Following Japan's Biggest Stock Surge in 7 Years

U.S. Stocks Open Higher Following Japan's Biggest Stock Surge in 7 Years

U.S. stocks open sharply higher Wednesday. Wall Street followed a 7.7 percent gain in Japan's Nikkei Stock Index, the biggest percentage gain since October 2008.

What Stocks Are Value Investors Buying?

Not many, according to filings from Tweedy Browne and Kahn Brothers.